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Oncolytic virotherapyOncolytic virotherapy is a new modality of cancer treatment which uses competent replicating viruses to
destroy cancer cells. This field progressed from earlier observations of accidental viral infections causing
remission in many malignancies to virus drugs targeting and killing cancer cells. More competent and
specific viruses which attack tumor cells but not healthy cells could be made with advancements in
the field of genetic engineering. Studying virus as a drug has benefits of secure handling of all aspects
related to this advancing field. In many ways virus given for treatment is comparable to a drug. The virus
lies in the grey area of life and death and thus outside the body it is same as an unopened drug. Once
inside a biological system, it starts acting targetting specific systems sine qua non as a drug. This review
compares virus to a drug and deals with its pharmacokinetics, pharmacodynamics, virus drug interac-
tions and combination virotherapy of this new treatment modality.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
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Cancer treatment is ever-changing, and researchers are in
search of newer modalities to fight cancer. It was a known fact that
certain viruses have oncolytic or cancer-killing properties. There
were reports of chickenpox infection improving the WBC (White
Blood cells) count and lymph node status in patients with lympho-cytic leukaemia [1]. Measles caused an improvement in the case of
leukemia, Hodgkin’s, and Burkitt’s lymphoma [2]. A lot of research
is going on in this field utilizing this property of virus to make new
treatment options for cancer. Using genetic engineering better
virus are created which have more specificity for its action. Chinese
state FDA (Food and Drug Administration) approved the first onco-
lytic virus-drug ‘ONCORINE’ an Adenovirus type 5 injection in 2005
for head and neck malignancy [3]. Many new viral drugs are on
trial for metastatic malignancies like malignant melanoma. In
October 2015 the US FDA approved a genetically engineered her-
pes virus called talimogene laherparepvec (T-VEC) to treat
advanced melanoma [4]. T-VEC is genetically modified so that it
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destroys it. More candidate viruses are under trial for its oncolytic
potential. The viruses kill neoplastic cells as well as trigger
immune response against the tumor. Virotherapy along with
chemotherapy, i.e., combination virotherapy, may fill the lacunae
of current treatment options by reducing adverse events as it has
specificity for cancer cells.2. Virus kinetics
2.1. Dosage and administration
To begin with, we need to have an idea of the dosage form of
virus drug. The dosage of the virus is measured using several meth-
ods, e.g., TCID50 (50% Tissue Culture Infective Dose) a measure of
the infective virus titer, plaque forming units (pfu), Focus forming
assay, Haemagglutinin assay, electron microscopic methods, TRPS
(Tunable Resistive Pulse Sensing), etc. Adequate dosage is required
for the significant action of the virus at the tumor site. Studies in
measles virus (Moraten strain) showed that for efficient antitumor
activity, Moraten dose more than 108 TCID50 is needed, which was
assessed by the prolonged survival after administration of the
strain in the murine intraperitoneal model of human ovarian can-
cer. Therapeutic range studies of the virus can be done to deter-
mine the dose which matches the efficacy and safety of virus
drug. In mice, doses up to 1  107 plaque forming units (pfu) of
the second generation HSV inoculated into brain resulted in no
adverse effects [5,6]. Measles virus given as a single intravenous
dose of 4  106 TCID50 per kilogram caused tumor regression
and prolongation of survival in KAS-6/1 myelomamodel [2]. Unlike
drugs which can be readily prepared in any concentrations, there is
difficulty in getting a maximum concentration of virus drug to
mark the actual start of toxicity. It is practically possible only in
few cases. In the virus, JX-594 maximum tolerated dose was 1 
109 pfu [7,8]. Drugs are given at lower doses and given more fre-
quently considering the half-life so that adequate concentration
is reached without causing a much toxic effect. Safer viral drugs
are also available which can be provided in more massive doses.
ONYX 015, even when administered up to 1011 pfu did not cause
any dose-limiting toxicity [9]. Virus infection in cancer cells and
its destruction induces an immune response against cancer cells
as many tumor antigens get exposed to the immune system. There
is a dose-dependent increase in levels of the inflammatory cytoki-
nes like IL-6 and IL-8 released by malignant melanoma cells upon
infection with measles virus. This increase shows the need of opti-
mal dosage for the bystander response also [9]. Threshold dose to
ensure that the virus acts on tumors can be calculated by conduct-
ing dose range studies and doing tumor biopsies to recover the
virus. JX594, an oncolytic vaccinia virus is under trial for non-
resectable hepatocellular carcinoma appeared in tissue biopsies
only when the threshold dose was more than 109 infectious units
[10].2.2. Distribution of virus
Viral titer, which is similar to drug concentration measures the
in vivo distribution of the viral drug. As the virus causes cytolysis,
it releases some detectable molecules which can be used to assess
the activity indirectly. Adeno virus used in the treatment of pro-
static adenocarcinoma if infects the tumor cells significantly, cause
PSA (Prostate-specific Antigen) to rise by many times, which con-
firm its effect [11]. The virus levels may spike several times over
a period due to replication [12]. Due to this; the total viral load will
increase that which was introduced. There are other ways to study
the in vivo monitoring of the spread of the oncolytic virus. Visualanalysis of distribution can be done using fluorescent labelling of
the vector with isothiocyanate [11]. By genetic engineering of the
viral genome, transcription units coding for soluble marker pep-
tides is inserted. When the virus infects the cells, this soluble sub-
stance is secreted from the cell to detect it quickly from the body
fluids. In case of measles virus, b-hCG (b sub-unit of human chori-
onic gonadotropin) and soluble extracellular domain of CEA
(human Carcino Embryonic Antigen) is used for this purpose
[13]. So once a virus infects the cells, this soluble marker starts
appearing in the blood and urine and thus confirms the infection
and not mere excretion of the agent or destruction by the immune
system.
In the case of measles virus, a recombinant version that codes
human thyroidal sodium iodide symporter (NIS) is added [14]. So
the infected cells, with the help of this symporter concentrates
iodine in the cells. Radioactive iodine given through the intra-
venous route gets concentrated only in the virus-infected cells by
the uptake through NIS. Radioactivity measured by serial SPECT
(Single Photon Emission Computed Tomography), serial gamma
camera imaging of iodine-123 or PET (Positron Emission Tomogra-
phy) at the site of tumor confirms the action of a virus on the
tumor. A Vaccinia virus GLV-1h153 engineered to carry the human
sodium iodide symporter (hNIS), facilitated detection by PET with
both intratumoral and systemic administration. Dana et al. studied
the tissue distribution, spread of GLV-ih153 and timing dynamics
between viral infection, uptake of radioiodine and oncolysis in
human pancreatic carcinoma cells [15]. A benefit of virus drug is
that its action can be confirmed by immunohistochemistry
method. G207, another second generation oncolytic HSV virus is
a multimutated virus with both copies of c34.5 gene deleted and
E. coli LacZ gene inserted. Histochemical detection of b-
galactosidase helps to confirm and monitor the preferential affinity
of the virus to glioma cells instead of healthy neural tissue [16].
Distribution in tissues depends on the chemical properties of the
drug. More lipophilic molecules will spread easily through the
body and will have a higher volume of distribution. Entry of drugs
into the central nervous system is limited due to tight junctions
which form the blood-brain barrier. This limitation can be circum-
vented by using new drug delivery methods like CED (Convection
Enhanced Devices). CNS tumors can also be targeted by using a
virus like Parvo virus which, unlike other oncolytic viruses crosses
the blood brain barrier and attack the tumor cells [17].
2.3. Metabolism and excretion
The main route of elimination of virus drug is by the immuno-
logical mechanism. But studies have not shown much correlation
between viral titers and increasing anti-viral antibody titer. Antitu-
mor action persisted in spite of high antibody response against
them [18]. O’Riordan and colleagues described PEGylation of virus
that is adding polyethylene glycol covalently to the protein cover-
ing of Adenovirus. It prevents the immunogenicity of the virus,
prevents antibody binding, and increases the solubility and thus
the serum half-life [19]. The Virus will concentrate in the reticu-
loendothelial system, and from there it is slowly removed by
immune-mediated mechanisms. Preconditioning the MPS scav-
enger receptors or by destroying the macrophage or endothelial
cells can reduce this loss. In animal studies, it is seen that polyi-
nosinic acid, which will bind to the scavenger receptors will reduce
the sequestration of adenovirus [15]. Clodronate-loaded liposomes
can destroy the liver Kupffer cells and splenic macrophages in mice
[20]. Some cells can function as vehicles for the therapeutic virus.
The cell carriers can be solid tumor cells, Hematological malignant
cells, Xenogeneic/allogeneic cells, T cells, CIKs, mesenchymal stem
cells, neural stem cells, etc. An efficient carrier should have a nat-
ural habit of being at the tumor site. This vehicle should pass
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other deregulated homeostasis. Once in tumor environment, they
should act like a source for virus production. Stem cells are
attracted towards certain substances called chemo attractant
molecules and also some receptors in the tumor cells, like SDF1/
CXCR4, VEGF/VGFFR, growth factors, and chemokines, etc., which
are expressed more in cancer cells during uncontrolled growth
and thus are tried for this.3. Virus dynamics
The infectivity of a virus can be assessed quantitatively using
Multiplicity of infection (MOI) ratio. It is the ratio of infectious
agents to the targets. As the MOI increases the percentage of cells
infected with at least one viral particle also increases.
3.1. Receptor mediated mechanism
Viruses will have an affinity towards different receptors. It is
found that CD46 (membrane co-factor protein) is overexpressed
in cancer cells compared to normal cells to protect them from com-
plement mediated destruction. This is seen in leukemias, multiple
myeloma, gastrointestinal, hepatocellular, colorectal, endometrial,
cervical, ovarian, breast, renal, and lung carcinomas. Measles virus
has a tropism to CD46, and they use these receptors to enter into
the cells [21,22]. It is known that the cytopathic effect of measles
infection is syncytium formation due to cell-cell fusion. CD46 has
a role in cell-cell fusion also. A particular threshold CD46 density
is required for this system formation to occur following the infec-
tion so that the normal cells are more resistant to measles attack.
Also, the measles used is attenuated as the wild type is not found
to act via CD46 mechanism but by SLAM (Signalling Lymphocytic
activation molecule) mechanism [23]. Adeno virus B1 species uses
CD46, and B2 species use DSG-2 (Desmoglein-2) for cell entry [24].
There is another fiber knob: CAR-mediated pathway (Coxsackie
and Adenovirus receptor) used for cell entry which is an important
receptor pathway for oncolysis. Tuve et al. found that Ad11 utilizes
another unidentified receptor called ‘receptor X’ which is signifi-
cant in cancer cell entry [25]. NSLC (Non-Small Cell Lung Cancer)
expresses high levels of CAR and DAF (Decay Accelerating factor).
The oncolytic activity of CVB3 (Coxsackie B3 virus) is found to be
proportional to the percentage of CAR expressing cells times the
percentage of DAF expressing cells [26]. CD20 is a receptor seen
in normal and neoplastic B cells but not in other tissues. Rituximab
is a CD20 monoclonal antibody in use against NHL (Non-Hodgkin’s
Lymphoma). Use of a CD20-targeted recombinant measles virus
can be used as a substitute to Rituximab in the FCR (Fludarabine,
Cyclophosphamide, and Rituximab) regimen for lymphoma man-
agement [27]. PVS-RIPO, a novel oncolytic virus consist of the gen-
ome of Sabin strain polio virus type 1 and human rhinovirus type 2
(HRV2) internal ribosomal entry site (IRES). It has an affinity for
CD155 which is up regulated in neurectodermal malignancies like
high grade gliomas and thus is under trial for such malignancies
[28]. In many other virus infections, the actual receptor on which
virus gets attached is unknown, or they may enter via interaction
with different types of receptors. Sindbis virus is an alpha virus
that can interact with heparin sulphate (HS) moiety and mediates
its oncolytic activity
3.2. Aberrant signalling pathway in cancer cells
Interferons have anti-viral and anti-proliferative properties.
Their antiviral mechanism involves activation of PKR pathway,
2–5 A synthases and activation of some specific proteins. PKR gets
activated if comes in contact with ds RNA derived from the virus. Itphosphorylates itself and other substrates like eIF2 which is a
translation initiation factor of viral translation. Phosphorylation
leads to eIF2 inactivation and thus inhibition of virus and host pro-
tein translation. They act at different levels in different viral infec-
tions. E.g. they inhibit genomic transcription of Influenza virus, but
interferes with protein translation of Adeno virus. It is said that the
mutation lies in the heart of carcinogenesis. Mutations help in the
proliferation of the cancer cells. As interferons inhibit growth, pro-
liferation, cancer cells will switch the genes off for its better sur-
vival and proliferation thus making them susceptible to easy
viral entry and spread to neighboring cells. The inherent properties
of cancer cells make them more susceptible to viral invasion. Reo
virus multiplies specifically in cells with activated RAS pathway,
sparing normal cells. RAS inhibits PKR pathway and enhances viral
infectivity thus can be used in tumors with an aberrant RAS path-
way, especially solid tumors [29]. Infected cells mostly undergo
apoptosis, but some tumor cells are resistant to normal apoptotic
pathways which may not respond to this treatment.3.3. Augmenting immune response against cancer
Cell death or cytolysis of the cancer cells exposes cancer antigen
to the circulation and launches an immune response against the
same. The antigen presenting cells presents the tumor associated
antigen (TAA) to the T cells, which carry out further cell killing.
Augusto et al. used Adeno viral vector with HSV-TK protein which
functions as a super antigen and stimulates T cells and secretion of
cytokines like IL-2 [30]. The release of tumor antigens evokes a sys-
temic response against homologous tumors metastasized. So the
local intratumoral injection of viruses will have a global effect.
The long-term effect of the viruses is due to this immunological
activation. Working on the immunological memory may further
prevent the relapse of the tumor. The immune system may not
be successful against large, bulky tumors, but against residual
tumors it can have a significant action. The Virus itself will increase
the IFN-gamma levels in the blood, which also helps in anti-tumor
action [31].4. Combination virotherapy
Cyclophosphamide is highly toxic to the immune system, so
giving it along with virus drug will suppress the anti-viral immune
response. Pre-administering of cyclophosphamide prevents clear-
ance of viral particles and increases HSV replication in glioma
[32]. Many preclinical studies demonstrate that cyclophosphamide
is better than dexamethasone in this aspect. Reo virus is found to
be well tolerated by the patients along with cyclophosphamide.
G207, NV1020, and 1716 are tested with chemotherapy with better
results. It was found that G201-cisplatin combination therapy
achieved 100% cure rate in case of cisplatin sensitive human head
and neck squamous cell carcinoma in animal models [12].
Increased efficacy is noted in 1716 plus mitomycin in a human
lung cancer mode. ONYX-015 and either cisplatin or 5FU for head
and neck cancer or metastatic colorectal cancer showed good
results. Histone deacetylase inhibitors (HDAC) inhibited the
already limited interferon response of tumor cells, thus increasing
the effect of co-administered virus drug. This has been tried in pox
virus (vaccinia) which showed an increased survival of mouse
bearing colon tumor xenografts HCT116 [33]. Rapamycin enhances
the growth of many viruses by attacking the TORC1-dependent
production of interferon and disrupting the phosphatidylinositol
3-kinase AKT pathway. SVV-001 is administered with Rituximab
to reduce the immune response [34]. Lytic activity of NV1020
was enhanced with radiation in HuH7 xenografts in athymic mice.
G207 and radiation in cervical cancer are found to have increased
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tion sensitive p-53 mutant cell line. The potency of NIS-
expressing virus can be increased by administering I-131, which
delivers high-energy beta particles, into the infected tumor [14].
Combining treatments can be done using recombinant DNA
technology. ONCOS-102 is a chimeric Ad5/knob3 vector added
with GM-CSF production has completed phase-1 trial in advanced
solid tumors [35]. GM-CSF is a potent immunostimulator which
augments CD8 + T cell response. Ganesh et al. used hyaluronidase
enzyme along with Ad5/35GFP fiber-chimeric adenovirus which
enhanced virus transduction and spread within prostate cancer
[22]. Losartan is an angiotensin receptor blocker used for control
of hypertension. It enhances the intratumoral spread of oncolytic
HSV as it disturbs the transforming growth factor beta1 signalling.
This results in reduced collagen production and fibrotic activity
helping the easy spread of the virus inside the tumor [36]. But it
takes some time for its action. The vascular permeability of tumor
blood vessels can be increased so that the effect of both virus, as
well as drugs, can be enhanced. VEGF (Vascular Endothelial
Growth Factor) plus paclitaxel or cisplatin increases it and thus
improves the delivery of Sindbis virus into tumors [12]. Similarly,
in the B16 melanoma model, a combination of VEGF165 and reo-
virus resulted in enhanced infection of the tumor [37]. Adeno virus
delivered to the tumor bed following surgical resection, radiother-
apy, or chemotherapy in prostatic carcinoma reduced the develop-
ment of secondaries in the lungs as well as local recurrence.
Combining virus with complementing virulence proteins can be
done. Interferon sensitive VSV, which is an RNA virus is combined
with the pox virus encoding a secreted interferon antagonist had a
better oncolytic effect by VSV and better intratumoral spread due
to pox.5. Conclusion and future prospective
Oncolytic viruses initially can be tried as an add-on therapy for
malignancy, then trying to replace it if found to be effective.
Utilization of recombinant DNA technology to engineer the best
killer virus which targets only cancer cells is the future. It should
have a very high margin of safety and cost should be less for the
benefit of all. Proper regulations regarding assessing the bioavail-
ability, bioequivalence, standard of procedure for use, guidelines
for health workers all need to be made available for this therapy.
More and more phase 2/3 trials should be done to confirm the
effectiveness of the virus drug as very few drugs has reached the
phase 3 trials. Utilizing the advances in the fields of recombinant
DNA technology, virology and pharmacology will help to achieve
this target and help to place these virus drugs in the standard treat-
ment of clinical oncology shortly.
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